je.st
news
Tag: merck
Merck animal health investing in swine vaccine innovation, manufacturing and people
2016-11-14 10:00:00| National Hog Farmer
SPONSORED Merck Animal Health shares how they are driven by prevention and making investments in swine vaccine innovation, manufacturing and people. read more
Tags: people
health
animal
manufacturing
Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
2016-11-13 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Phase 2 Data Presentations at The Liver Meeting Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the companys investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Language: English Contact: Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Announces Presentation of New Findings for ZEPATIER (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting
2016-11-12 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from multiple analyses at The Liver Meeting 2016, which provide additional evidence supporting the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or GT4-infected patient populations, including those who receive opioid agonist therapy (OAT), are infected with chronic HCV GT1b, use proton pump inhibitors (PPIs) or have moderate kidney disease.
Tags: the
meeting
presentation
patients
Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
2016-11-02 21:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results of First Phase 3 Trial Anticipated in Late 2017 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimers disease (AD). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orIan McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: research
development
science
early
Merck Prices EUR 1.0 Billion Debt Offering
2016-10-26 19:31:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, priced today a EUR 1.0 billion public offering of two series of Euro-denominated senior unsecured notes (collectively, the New Notes). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0 billion equates to approximately $1.087 billion. The notes include: EUR 500 million of 0.500% notes due Nov. 2024EUR 500 million of 1.375% notes due Nov. 2036 Language: English Contact: Merck & Co., Inc.Media:Lainie Keller, 908-236-5036Tracy Ogden, 267-305-2301orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: eur
prices
offering
debt
Sites : [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »